Skip to search formSkip to main contentSkip to account menu

naloxegol

Known as: (5?,6?)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol, Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)- 17-(2-propenyl)-, (5alpha,6alpha)- 
A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (3)

MorphinansNarcotic AntagonistsPolyethylene Glycols

Narrower (3)

MovantikNKTR-118naloxegol oxalate
naloxegol 12.5 MG Oral Tabletnaloxegol 12.5 MG Oral Tablet [Movantik]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation
Objectives: To determine patient preference for treating opioid-induced constipation (OIC) using naloxegol or polyethylene glycol… 
Review
2018
Review
2018
New developments in the treatment of opioid-induced gastrointestinal symptoms
Chronic pain affects a large part of the global population, leading to an increase of opioid use. Opioid-induced constipation… 
Review
2017
Review
2017
Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
Opioid-induced constipation (OIC) imposes a significant burden for patients taking pain medications, often resulting in decreased… 
Review
2016
Review
2016
Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014
Regulatory approval documents contain valuable information, often not published, to assess the drug–drug interaction (DDI… 
2016
2016
The Effect of Quinidine, a Strong P‐Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol
I read with interest the article by Bui and colleague, titled “The Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the… 
Review
2015
Review
2015
Naloxegol, a new drug for the treatment of opioid-induced constipation
Introduction: With increasing chronic opioid use, opioid-induced constipation (OIC) is becoming a relevant clinical challenge… 
Review
2015
Review
2015
Clinical utility of naloxegol in the treatment of opioid-induced constipation
Opioids are a class of medications frequently used for the treatment of acute and chronic pain, exerting their desired effects at… 
Review
2015
Review
2015
Advances in pharmacotherapy for opioid-induced constipation – a systematic review
Introduction: Opioid-induced constipation (OIC) is one of the most frequent and burdening adverse events (AE) of opioid therapy… 
2015
2015
Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol
Opioid‐induced constipation (OIC) is the most common and often a treatment‐limiting adverse event (AE) of opioid therapy for… 
2014
2014
The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol
The impact of renal impairment on the pharmacokinetics of a 25‐mg oral dose of naloxegol was examined in patients with renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)